GlassScriptPhysician profile
Jinal Patel
NPI 1043944002
$3,505.13
in general payments reported to CMS, 2019-2025
28 companies · $1,277 in 2025
The $1,277 reported for 2025 was more than what 90% of Family providers received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $161 · 2023: $1,029 · 2024: $1,038 · 2025: $1,277.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,344.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,344.21 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $709.69 | 2022-2025 | Mounjaro, Jardiance |
| Astrazeneca Pharmaceuticals LP | $410.47 | 2023-2025 | Airsupra, Breztri, Farxiga |
| Novo Nordisk INC | $329.04 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $299.54 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Nestle Healthcare Nutrition INC. | $200.65 | 2023 | |
| Daiichi Sankyo INC. | $157.72 | 2022-2025 | Injectafer |
| Polynovo North America LLC | $140.80 | 2025 | Novosorb Btm |
| Otsuka America Pharmaceutical, INC. | $123.06 | 2022-2024 | Rexulti |
| Boehringer Ingelheim Pharmaceuticals, INC. | $121.53 | 2023-2025 | Jardiance, Synjardy |
| Angiodynamics, INC. | $114.64 | 2025 | Auryon Laser System 100-120 Vac |
| Shionogi INC | $111.75 | 2024 | Fetroja |
| Astellas Pharma US INC | $109.01 | 2025 | Cresemba |
| Abbvie INC. | $91.40 | 2023 | |
| Medtronic, INC. | $85.00 | 2023 | Contour 3d |
| Pfizer INC. | $74.76 | 2023-2025 |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $64.31 | 2022-2024 | |
| Exact Sciences Corporation | $57.48 | 2023-2025 | Cologuard Collection Kit |
| Biohaven Pharmaceutical Holding Company LTD. | $56.35 | 2022 | |
| Idorsia Pharmaceuticals US INC | $42.83 | 2023 | Quviviq |
| Avadel Cns Pharmaceuticals, LLC | $34.32 | 2025 | Lumryz |
| Dynavax Technologies Corporation | $33.47 | 2025 | Heplisav-B |
| Dexcom, INC. | $26.95 | 2024 | Dexcom G6 Transmitter |
| Thea Pharma INC. | $22.40 | 2025 | Iyuzeh |
| Aimmune Therapeutics, INC. | $20.40 | 2025 | Zenpep |
| Currax Pharmaceuticals LLC | $17.48 | 2023 | Nexletol, Nexlizet, Contrave |
| Phathom Pharmaceuticals, INC. | $17.06 | 2024 | Voquezna |
| Ironwood Pharmaceuticals, INC | $16.52 | 2025 | |
| Merck Sharp & Dohme LLC | $16.50 | 2025 | Gardasil 9, Capvaxive |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jinal Patel listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.